AI for pharma and pharmaceutical companies: from CMC dossier to pharmacovigilance

Pharma, biotech and MedTech organisations work in an environment where any automated system can be GxP-relevant. From clinical research to batch release, from eCTD submissions to signal detection in adverse events: AI offers enormous time savings, but only if the solution fits within 21 CFR Part 11, EU GMP Annex 11, GAMP 5 and the latest EMA guidelines on artificial intelligence. We build AI solutions that your QA department can validate, with no compromises on data quality, audit trails or patient safety.

Document AI for CMC and IND/NDA Pharmacovigilance signal detection GDP cold-chain optimisation Clinical trial recruitment Predictive QC in manufacturing CSV and GAMP 5 compliant
Discuss your pharma AI case View use cases
Adverse Event Signals Cold-chain GDP

Why pharma needs its own AI approach

A general LLM implementation that works perfectly well in retail or marketing won't meet the requirements in pharma. As soon as an AI system affects product quality, batch release, clinical decisions or pharmacovigilance, it falls under GxP and must be validated in line with GAMP 5. The architecture choices you make in that context are radically different from those in non-regulated sectors.

A biotech start-up running a phase II clinical study collects data from electronic CRFs, ePRO apps, lab LIMS and wearables. A large pharma company works its way through eCTD modules, MedDRA codings, ATC classifications and MES events from production lines that send out sensor data every second. In both cases, AI promises a speed-up: less manual review of CMC documents, faster patient recruitment, earlier detection of deviations in the cold chain. But every model that goes into production has to be auditable, not just for your own QA, but also for the FDA, EMA, the Dutch CBG or a GCP inspector who wants to reconstruct your decision-making process years later.

That is why we always approach AI in pharmaceutical environments from two questions: does it deliver a measurable benefit in time, cost or patient safety, and can the system be validated without the validation overhead cancelling out that benefit? Sometimes that means a classifier running inside a validated document management system. Sometimes an LLM-based assistant with strict guardrails outside the GxP perimeter. And sometimes, which is a legitimate answer, no AI at all, because a rule-based solution is enough and easier to validate.

Core areas where AI adds value in pharma

From regulatory affairs to manufacturing, AI touches almost every link in the pharmaceutical value chain. Each area has different validation requirements and different risk classifications.

๐Ÿ“‘

Document AI for CMC, IND and NDA

The CMC sections of an eCTD submission quickly run to thousands of pages. An AI pipeline extracts specifications, batch data, stability data and cross-references from Module 3, compares them with earlier submissions and flags inconsistencies. Regulatory writers stay in control of the content; the tool removes the searching and checking. Suitable for both innovator files and generic ANDA routes.

๐Ÿšจ

Pharmacovigilance and signal detection

Adverse event reports arrive via E2B(R3), call centres, social media and literature. NLP models normalise free text into MedDRA Preferred Terms, link them to ATC codes and flag statistical disproportionality. Your PV team no longer works through individual cases but through structured signals, with a complete audit trail that supports PSUR and RMP updates.

โ„๏ธ

Cold chain and GDP optimisation

Distributing temperature-sensitive products falls under GDP. AI models analyse IoT sensor data from cold chains, predict temperature excursions before they happen and optimise routes and buffer locations. The result: fewer excursions, fewer discarded batches, fewer deviation reports. It connects to your existing WMS and TMS systems and respects their validation status.

๐Ÿงช

Clinical trial recruitment and retention

A phase III study more often stumbles on recruitment than on science. AI models analyse EHR data (within legal frameworks) and public registries to identify suitable patients at trial sites, predict no-shows and flag retention risks. EU CTR-compliant, with explicit consent flows and pseudonymisation in line with GDPR and HIPAA.

โš™๏ธ

Predictive QC in manufacturing

MES and SCADA data, in-line PAT sensors and LIMS results together provide enough signal to predict deviations in a batch before final inspection takes place. The models run alongside your release criteria, not in place of them. Implementation takes 21 CFR Part 11 audit trails into account, as well as the validation regimes of Werum PAS-X, Aspen or comparable pharma ERP platforms.

๐Ÿ“‹

Regulatory affairs automation

Health authority queries, change control, labelling updates and periodic safety updates rely heavily on written work. AI supports regulatory teams with draft generation, cross-checks between SmPC versions and automatic tracking of regulatory changes at the EMA, FDA and local authorities. Output is always reviewed by a regulatory affairs manager before submission.

How Appfront builds AI within pharma organisations

We don't deliver an off-the-shelf pharma platform. Pharma is too diverse for that: a MedTech start-up with a single SaMD product has different needs from an established manufacturer with ten manufacturing sites and hundreds of marketed products. Our role is that of build partner: from data assessment to validation support to production implementation within your existing IT and QA landscape.

From day one we work alongside your QA, validation and regulatory functions. A use case that is GxP-relevant immediately gets a Computer System Validation strategy in line with GAMP 5: risk classification, URS, FS, configuration baseline, IQ/OQ/PQ protocols and ongoing periodic reviews. Not GxP-relevant? Then we opt for a lighter regime, but we document explicitly why, so that a later reclassification comes as no surprise.

Our approach is iterative. We start with a proof of concept on a well-defined set of pseudonymised data: for example, a document classifier on a subset of your CMC archive, or a signal-detection model on historical E2B data. Only once the POC proves that it works and we can see a route to validation do we move to production. That saves you a multi-year validation project that ends without end-user acceptance.

From use case selection to validated production

Our approach to AI in pharma follows four phases. Each phase ends with a tangible deliverable that your QA, regulatory and business stakeholders can review together, with no big-bang implementation without interim results.

GxP assessment

Together we determine whether the use case is GxP-relevant, which GAMP 5 category applies and which regulations are affected: 21 CFR Part 11, Annex 11, EU CTR, the EMA AI Reflection Paper or the AI Act for MedTech. Output: an agreed scope and risk baseline.

Proof of concept

Within a few weeks we build a working prototype on pseudonymised data: a classifier on CMC documents, a signal-detection pipeline on historical adverse events, or a predictive model on MES data. Concrete, testable and without validation overhead.

Validation and integration

If the POC delivers a positive outcome, we draw up the URS, FS and validation protocols in line with GAMP 5. Integration with your DMS, LIMS, MES, ERP-Pharma or safety databases takes place via validated interfaces with audit trails compliant with 21 CFR Part 11 and Annex 11.

Periodic review

AI models don't perform forever. We provide monitoring of model drift, periodic retraining and the associated change controls. This includes documentation for inspections by the FDA, EMA or national regulators such as the Dutch Health and Youth Care Inspectorate (IGJ).

Technology we use in pharma projects

Our choice of stack depends on the regulatory context. For GxP systems we choose frameworks with deterministic behaviour, reproducible builds and strong audit-trail capabilities. For document AI we work with transformer models that we fine-tune on pharma-specific corpora (pharmacopoeia text, SmPCs, CMC sections), so that the model is familiar with specialist terminology such as USP, Ph. Eur., dissolution profiles and API/excipient specifications.

For signal detection in pharmacovigilance we use models that predict MedDRA codings from free text, combined with classic disproportionality methods (PRR, ROR, IC). For cold chain and manufacturing we choose time-series models that remain transparent: no black-box deep learning on production processes that inspectors can pick apart without a clear answer to the "why" question.

Python PyTorch Hugging Face Transformers scikit-learn XGBoost LangChain FastAPI PostgreSQL Apache Airflow Docker Kubernetes Veeva Vault API Werum PAS-X SAP S/4 Pharma LIMS integration
Not sure about a large project yet?

Test your idea first: a working prototype in 1 day

With OneDayBuild, we make your idea tangible in a single day for โ‚ฌ1,150, so you know whether further development is worth the investment. Decide to go ahead with the full build? Then we deduct the cost in full.

View OneDayBuild โ†’

Compliance: GxP, CSV and the AI Act in one architecture

An AI solution that QA doesn't approve delivers no value. From the first sprint, we design with validation in mind: not as an afterthought, but as an architectural starting point.

21 CFR Part 11 and Annex 11

Audit trails, electronic records, electronic signatures and data integrity (ALCOA+) are non-negotiable. We implement append-only logging, role-based access control, secure timestamping and complete record-level change history. Documentation aligns with your existing SOPs for electronic records.

GAMP 5 and CSV

Computer System Validation according to GAMP 5 is our guiding framework. We classify every component (Category 1 to 5), draw up a differentiated validation strategy and deliver URS, FS and IQ/OQ/PQ protocols in a form that fits your QMS. For AI components, we apply the GAMP 5 Second Edition guidance.

EMA AI Reflection Paper and the AI Act

The EMA's reflection paper on AI in the medicinal product lifecycle and the EU AI Act (high-risk classification for MedTech and parts of pharma) help determine the requirements for transparency, robustness, human oversight and post-market monitoring. We translate these into concrete architectural choices and governance documents.

GDPR, HIPAA and data hosting

Patient data, clinical data and AE reports are special categories of personal data. We host in EU data centres, use pseudonymisation during training, and conclude data processing agreements with technical and organisational measures that can withstand scrutiny from the Dutch Data Protection Authority (AP), the Dutch Health and Youth Care Inspectorate (IGJ) and foreign regulators. No cross-border data flows without a substantiated legal basis.

Concrete scenarios within pharmaceutical organisations

AI in pharma is not a pipe dream. With the current state of the art, the applications below are well within reach to build and validate, provided the scope is designed correctly from the start.

CMC classifier for a Module 3 archive

A mid-size pharma company wants to check every new submission for consistency with earlier CMC sections. A document classifier and NER pipeline extracts specifications, method descriptions and stability data from Module 3. Regulatory writers automatically receive diff reports against historical submissions, so cross-reference errors are caught at the draft stage.

Signal detection on E2B(R3) ICSR feeds

A PV team processes thousands of ICSRs per month. An NLP pipeline normalises free-text narratives to MedDRA Preferred Terms and LLT codes, links them to ATC classifications and then runs disproportionality analyses. Triage decisions remain with the PV officer; the tool delivers a structured shortlist with supporting evidence, which is useful for PSUR and RMP updates.

Cold-chain anomaly detection

A wholesaler with a GDP licence receives sensor data from hundreds of shipments every day. A model predicts temperature excursions based on route, vehicle, weather forecast and per-carrier history. Operations step in before the excursion occurs, deviation reports decrease, and the value of rejected batches demonstrably falls.

Patient recruitment for clinical research

A biotech start-up is looking for phase II patients with a specific mutation profile. An AI pipeline searches structured EHR fields in participating hospitals and public registries, within consent boundaries and with strict pseudonymisation. Site coordinators receive a list of suitable candidates with the supporting rationale for each criterion, in line with the EU CTR and GCP.

Why Appfront for AI in pharma

Industry jargon and regulation as the starting point

We know the difference between an SmPC and an IB, between a PSUR and an RMP, and between the GxP categories within GAMP 5. We translate that domain language directly into architecture, with no workshops needed to explain what an eCTD module is.

Validation as a design principle

CSV is not an afterthought but an input to the architecture design. From day one we build with audit trails, role-based access and deterministic builds โ€” not bolt-on QA after the fact, with all the rework that brings.

From POC to post-market

Many AI projects stall between prototype and production. We support the entire journey, including periodic review and model drift monitoring โ€” so an AI component is maintained as well as your other GxP systems.

Frequently asked questions about AI in pharma

When is an AI system GxP-relevant?
As soon as an automated system affects product quality, batch release, clinical data, patient safety or regulatory submissions, it falls under GxP. The specific classification follows from GAMP 5 (categories 1 to 5) and risk-based assessments. A chatbot for internal knowledge queries is usually not GxP-relevant; a classifier on CMC documents or a signal detector on AE reports almost always is.
How do you validate an LLM under 21 CFR Part 11 and Annex 11?
Probabilistic models call for an adapted validation approach. We work with deterministic input pipelines, pinned model versions, reproducible builds and extensive test suites with acceptance criteria on output quality. Audit trails record every prompt, model version and output. The EMA's AI Reflection Paper and the GAMP 5 second edition provide the guidance for risk-based validation.
Can patient data be used for AI training?
Under strict conditions. Pseudonymisation, explicit legal bases under the GDPR, a data processing agreement and โ€” depending on the context โ€” approval from a medical research ethics committee are requirements. We preferably work with synthetic data or aggregated pseudonymised datasets and host everything within the EU. Non-EU training clouds are only used if the legal basis holds up.
What does the EU AI Act change for MedTech and pharma?
MedTech software that qualifies as a medical device often falls under the AI Act's high-risk category, with additional requirements for risk management, data governance, technical documentation, transparency, human oversight and post-market monitoring. For non-device pharma applications the Act sometimes applies too (for example in HR or credit-scoring scenarios). We help with the classification and make sure your documentation satisfies both the MDR and the AI Act.
Can you integrate with Veeva, Werum PAS-X or SAP?
Yes. We build API integrations with Veeva Vault (RIM, QualityDocs, Clinical), Werum PAS-X MES, SAP S/4 Pharma, common LIMS packages and safety databases. Integration runs through validated interfaces with complete audit trails, so the AI layer fits within your existing system landscape without creating a shadow IT route.
What is a realistic timeline for a validated AI system?
A proof of concept on pseudonymised data is usually up and running within four to eight weeks. The timeline to full GxP validation and production depends on the use case, integrations, data quality and your internal validation process โ€” often several months to a year. We work in iterative sprints with interim stage gates, so investment only scales up once the system proves itself.

Deploying AI within your pharma organisation?

Discuss your use case with us. Together we map out whether the application is GxP-relevant, which validation route fits and what a realistic POC scope looks like.

Schedule a call

Edit content